Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis.

Arachidonic acid (AA) and its metabolites have recently generated a heightened interest due to growing evidence of their significant role in cancer biology. Thus, inhibitors of the AA cascade, first and foremost COX inhibitors, which have originally been of interest in the treatment of inflammatory conditions and certain types of cardiovascular disease, are now attracting attention as an arsenal against cancer. An increasing number of investigations support their role in cancer chemoprevention, although the precise molecular mechanisms that link levels of AA, and its metabolites, with cancer progression have still to be elucidated. This article provides an overview of the AA cascade and focuses on the roles of its inhibitors and their implication in cancer treatment. In particular, emphasis is placed on the inhibition of cell proliferation and neo-angiogenesis through inhibition of the enzymes COX-2, 5-LOX and CYP450. Downstream effects of inhibition of AA metabolites are analysed and the molecular mechanisms of action of a selected number of inhibitors of catalytic pathways reviewed. Lastly, the benefits of dietary omega-3 fatty acids and their mechanisms of action leading to reduced cancer risk and impeded cancer cell growth are mentioned. Finally, a proposal is put forward, suggesting a novel and integrated approach in viewing the molecular mechanisms and complex interactions responsible for the involvement of AA metabolites in carcinogenesis and the protective effects of omega-3 fatty acids in inflammation and tumour prevention.

[1]  U. Kelavkar,et al.  Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. , 2001, Carcinogenesis.

[2]  Marta L. Capone,et al.  New insights into COX-2 biology and inhibition , 2005, Brain Research Reviews.

[3]  F. Cianchi,et al.  Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells , 2006, Molecular Cancer Therapeutics.

[4]  S. Biswal,et al.  The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. , 1999, The Biochemical journal.

[5]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[6]  L. Magnelli,et al.  Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. , 2001, Neoplasia.

[7]  S. Grösch,et al.  Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. , 2006, Journal of the National Cancer Institute.

[8]  H. Ateş,et al.  Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines , 2005, Leukemia & lymphoma.

[9]  Charles N. Serhan,et al.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers , 2004, Lipids.

[10]  A. K. Katz,et al.  The 2.0 A resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase. , 2004, Journal of molecular biology.

[11]  A. Tenesa,et al.  Dietary fatty acids and colorectal cancer: a case-control study. , 2007, American journal of epidemiology.

[12]  J. Redfern,et al.  Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. , 1989, Gastroenterology.

[13]  S. Lippman,et al.  Advances in the biology of lung cancer chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Loll,et al.  Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. , 2001, Biochemistry.

[15]  M. Fornai,et al.  Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug , 2002 .

[16]  C. Serhan,et al.  Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Audoly,et al.  The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. , 2002, The Journal of clinical investigation.

[18]  R. DuBois,et al.  15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK1/2 signaling in colon carcinoma cells , 2004 .

[19]  R. Gaynor,et al.  Sulindac inhibits activation of the NF-kappaB pathway. , 1999, The Journal of biological chemistry.

[20]  J. Kleibeuker,et al.  Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas , 2003, The Lancet.

[21]  A. Brash,et al.  A single active site residue directs oxygenation stereospecificity in lipoxygenases: stereocontrol is linked to the position of oxygenation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Clynes,et al.  Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. identification of novel chemotherapeutic drug resistance modulators. , 2002, European journal of cancer.

[23]  Y. Kawahito,et al.  Relationship between lipoxygenase and human testicular cancer. , 2004, International journal of molecular medicine.

[24]  T. Ichikura,et al.  Expression of cyclooxygenase‐2 in human gastric adenomas and adenocarcinomas , 2001, Journal of surgical oncology.

[25]  B. Psaty,et al.  COX-2 inhibitors--lessons in drug safety. , 2005, The New England journal of medicine.

[26]  R. DuBois,et al.  Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Daya,et al.  Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons , 2006, Metabolic Brain Disease.

[28]  D. Grignon,et al.  Increased metastatic potential in human prostate carcinoma cells by overexpression of arachidonate 12-lipoxygenase , 2004, Clinical & Experimental Metastasis.

[29]  M. De Brabander,et al.  Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper , 2000, Gut.

[30]  C. Pan,et al.  Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. , 2001, Anticancer research.

[31]  A. Brash Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate* , 1999, The Journal of Biological Chemistry.

[32]  N. Narayanan,et al.  Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells. , 2001, International journal of oncology.

[33]  T. Grosser,et al.  Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.

[34]  Vincent Bours,et al.  Reactive Oxygen Intermediate-Dependent NF-κB Activation by Interleukin-1β Requires 5-Lipoxygenase or NADPH Oxidase Activity , 1999, Molecular and Cellular Biology.

[35]  G. Landberg,et al.  Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. , 2003, Gastroenterology.

[36]  M. Stampfer,et al.  A Prospective Study of Polyunsaturated Fatty Acid Levels in Blood and Prostate Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[37]  R. Dixon,et al.  Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis. , 1990, The Journal of biological chemistry.

[38]  J. Wallace,et al.  The therapeutic potential of NO‐NSAIDs , 2003, Fundamental & clinical pharmacology.

[39]  R. Sandler,et al.  Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs , 2002, Cancer.

[40]  Takao Shimizu,et al.  A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. , 2000, The Journal of experimental medicine.

[41]  A. Solhaug,et al.  Atypical lambda/iota PKC conveys 5-lipoxygenase/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta. , 2001, The Journal of biological chemistry.

[42]  R. Gaynor,et al.  Sulindac Inhibits Activation of the NF-κB Pathway* , 1999, The Journal of Biological Chemistry.

[43]  C. Moon,et al.  Phenidone, a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes , 2005, Brain Research.

[44]  Wei Li,et al.  Effects of a cyclooxygenase-1-selective inhibitor in a mouse model of ovarian cancer, administered alone or in combination with ibuprofen, a nonselective cyclooxygenase inhibitor , 2009, Medical oncology.

[45]  J. Palmblad,et al.  Interactions Between Lipoxin A4, the Stable Analogue 16‐phenoxy‐lipoxin A4 and Leukotriene B4 in Cytokine Generation by Human Monocytes , 2004, Scandinavian journal of immunology.

[46]  I. Zachary,et al.  Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen‐activated protein kinase , 1997, FEBS letters.

[47]  B. Wong,et al.  15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. , 2003, Carcinogenesis.

[48]  J. Falgueyret,et al.  Identification of 5-keto-(7E,9E,11Z,14Z)-eicosatetraenoic acid as a novel nonenzymatic rearrangement product of leukotriene A4. , 1993, Archives of biochemistry and biophysics.

[49]  J. Reginster,et al.  First clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis , 2002 .

[50]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1997, Nature.

[51]  G. Davı̀,et al.  5‐Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  A. Brash,et al.  Discovery of a second 15S-lipoxygenase in humans. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Gong Shusheng,et al.  Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2in vitro , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].

[54]  Sam W. Lee,et al.  Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways. , 2019, Cancer research.

[55]  M. Jett,et al.  Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism , 2007, BMC Cancer.

[56]  M. Thun,et al.  A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. , 2007, Journal of the National Cancer Institute.

[57]  J. Falck,et al.  Inhibitors of cytochrome P450 4A suppress angiogenic responses. , 2005, The American journal of pathology.

[58]  Jingxia Li,et al.  Nickel Compounds Render Anti-apoptotic Effect to Human Bronchial Epithelial Beas-2B Cells by Induction of Cyclooxygenase-2 through an IKKβ/p65-dependent and IKKα- and p50-independent Pathway* , 2006, Journal of Biological Chemistry.

[59]  K. Kinzler,et al.  Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Faivre,et al.  Chemoprevention of colorectal cancer. , 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[61]  Y. Urade,et al.  Prostaglandin D, E, and F synthases. , 1995, Journal of lipid mediators and cell signalling.

[62]  T. Tsukamoto,et al.  Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. , 2006, Gastroenterology.

[63]  R. Estabrook,et al.  Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Vapaatalo,et al.  Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. , 2003, Thrombosis research.

[65]  P. Zou,et al.  Role of Baicalein in the regulation of proliferation and apoptosis in human myeloma RPMI8226 cells. , 2006, Chinese medical journal.

[66]  Shadan Ali,et al.  A novel copper complex of 3‐benzoyl‐α methyl benzene acetic acid with antitumor activity mediated via cyclooxygenase pathway , 2007 .

[67]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[68]  F. Gürdöl,et al.  The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture , 2007, Clinical and Experimental Medicine.

[69]  T. Poulos Cytochrome P450: Molecular Architecture, Mechanism, and Prospects for Rational Inhibitor Design , 1988, Pharmaceutical Research.

[70]  L. Audoly,et al.  The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. , 2002, The Journal of clinical investigation.

[71]  J. Falgueyret,et al.  Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor , 1997, British journal of pharmacology.

[72]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[73]  R. Hanf,et al.  Cyclo‐oxygenase and lipoxygenase pathways in mast cell dependent‐neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve , 2001, British Journal of Pharmacology.

[74]  Y. Kawahito,et al.  Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. , 2003, The Journal of urology.

[75]  J. Morrow,et al.  A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. , 1997, Gastroenterology.

[76]  D. Zeldin,et al.  Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. , 2005, Cancer research.

[77]  Jilly F. Evans,et al.  Characterization of the Human Cysteinyl Leukotriene 2 Receptor* , 2000, The Journal of Biological Chemistry.

[78]  C. Godson,et al.  Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. , 2004, Kidney international.

[79]  D. Richel,et al.  Prostanoids and prostanoid receptors in signal transduction. , 2004, The international journal of biochemistry & cell biology.

[80]  N. V. Chandrasekharan,et al.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[81]  R. Busse,et al.  Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis , 2005, Journal of Cell Science.

[82]  D. Gilroy,et al.  Targeting lipoxygenases with care. , 2006, Chemistry & biology.

[83]  R. Mansel,et al.  Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[84]  C. Lines,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[85]  T. Moody,et al.  Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[86]  C. Lush,et al.  Regulation of intestinal nuclear factor-kappaB activity and E-selectin expression during sepsis: a role for peroxynitrite. , 2003, Gastroenterology.

[87]  S. Shahzidi,et al.  The effect of cyclooxygenase inhibitor diclofenac on experimental murine colon carcinoma. , 2003, Anticancer research.

[88]  M. Burdick,et al.  Cyclooxygenase-2-Dependent Expression of Angiogenic CXC Chemokines ENA-78/CXC Ligand (CXCL) 5 and Interleukin-8/CXCL8 in Human Non-Small Cell Lung Cancer , 2004, Cancer Research.

[89]  Lois E. H. Smith,et al.  Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis , 2007, Nature Medicine.

[90]  T. Inoue,et al.  Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors , 2008, Inflammopharmacology.

[91]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[92]  K. Hasegawa,et al.  Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. , 2005, International journal of oncology.

[93]  K. Hamada,et al.  Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. , 2008, Urology.

[94]  B. Anderson Paracetamol (Acetaminophen): mechanisms of action , 2008, Paediatric anaesthesia.

[95]  C. Serhan A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution , 2004, Histochemistry and Cell Biology.

[96]  C. Hawkey,et al.  COX‐LOX INHIBITION: CURRENT EVIDENCE FOR AN EMERGING NEW THERAPY , 2003, International journal of clinical practice.

[97]  R. de Caterina,et al.  The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKCε inhibition , 2006, Proceedings of the National Academy of Sciences.

[98]  I. Weinstein,et al.  Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. , 2003, Progress in experimental tumor research.

[99]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[100]  R. Busse,et al.  Cytochrome P450 2C9-induced Endothelial Cell Proliferation Involves Induction of Mitogen-activated Protein (MAP) Kinase Phosphatase-1, Inhibition of the c-Jun N-terminal Kinase, and Up-regulation of Cyclin D1* , 2002, The Journal of Biological Chemistry.

[101]  K. Malik,et al.  20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[102]  W. Zhou,et al.  Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer , 2005, Clinical Cancer Research.

[103]  Y. Hannun,et al.  Phospholipase A2 Is Necessary for Tumor Necrosis Factor α-induced Ceramide Generation in L929 Cells* , 1997, The Journal of Biological Chemistry.

[104]  E. Sigal,et al.  Defining the Arachidonic Acid Binding Site of Human 15-Lipoxygenase , 1996, The Journal of Biological Chemistry.

[105]  D. Goldenberg,et al.  Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. , 2002, Cancer research.

[106]  A. Plückthun,et al.  Rate-determining Step in Phospholipase A2 Mechanism , 1986 .

[107]  T. Uzu,et al.  Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. , 2007, Internal medicine.

[108]  Hee-Yong Kim Novel Metabolism of Docosahexaenoic Acid in Neural Cells* , 2007, Journal of Biological Chemistry.

[109]  I. Okayasu,et al.  Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance , 2004, Acta Neuropathologica.

[110]  S. Narumiya,et al.  Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors , 2007, Laboratory Investigation.

[111]  Guo-xian Ding,et al.  Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. , 2005, Japanese journal of clinical oncology.

[112]  L. Battistini,et al.  N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. , 2006, Kidney international.

[113]  R. Kamijo,et al.  Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. , 2001, European journal of cancer.

[114]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[115]  S. Lippman,et al.  Lipoxygenase modulation to reverse carcinogenesis. , 2001, Cancer research.

[116]  J. Dogné,et al.  New trends in dual 5-LOX/COX inhibition. , 2002, Current medicinal chemistry.

[117]  S. Narumiya,et al.  Prostaglandin D2 as a mediator of allergic asthma. , 2000, Science.

[118]  Luhua Lai,et al.  Dynamic Simulations on the Arachidonic Acid Metabolic Network , 2007, PLoS Comput. Biol..

[119]  S. Dey,et al.  Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.

[120]  H. Friess,et al.  5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. , 2002, The American journal of pathology.

[121]  R. de Caterina,et al.  The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[122]  A. Murakami,et al.  New class of linoleic acid metabolites biosynthesized by corn and rice lipoxygenases: suppression of proinflammatory mediator expression via attenuation of MAPK- and Akt-, but not PPARgamma-, dependent pathways in stimulated macrophages. , 2005, Biochemical pharmacology.

[123]  J. Haeggström Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis* , 2004, Journal of Biological Chemistry.

[124]  D. Reed,et al.  Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[125]  S. Higuchi,et al.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. , 1994, Prostaglandins.

[126]  P. Calder,et al.  Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. , 2005, Reproduction, nutrition, development.

[127]  R. Sartor,et al.  Low Endogenous Prostaglandin E2 Predisposes to Relapsing Inflammation in Experimental Rat Enterocolitis , 2004, Digestive Diseases and Sciences.

[128]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[129]  P. Jakobsson,et al.  Inhibition of prostaglandin E2 synthesis by SC‐560 is independent of cyclooxygenase 1 inhibition , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[130]  Y. Kakeji,et al.  Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. , 1997, Anticancer research.

[131]  A. Solhaug,et al.  Atypical λ/ιPKC Conveys 5-Lipoxygenase/Leukotriene B4-mediated Cross-talk between Phospholipase A2s Regulating NF-κB Activation in Response to Tumor Necrosis Factor-α and Interleukin-1β* , 2001, The Journal of Biological Chemistry.

[132]  P. Ridker,et al.  Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[133]  M. Jaye,et al.  Activation of Cytosolic Phospholipase A by Basic Fibroblast Growth Factor via a p42 Mitogen-activated Protein Kinase-dependent Phosphorylation Pathway in Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[134]  M. Hetzel,et al.  Inhibition of MMP-9 expression by PPARγ activators in human bronchial epithelial cells , 2003, Thorax.

[135]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[136]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[137]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[138]  S. Kulkarni,et al.  Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. , 2000, Methods and findings in experimental and clinical pharmacology.

[139]  T. Miller,et al.  Protection against ethanol injury by prostaglandin in a human intestinal cell line: role of microtubules. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[140]  J. Dyerberg,et al.  The composition of food consumed by Greenland Eskimos. , 2009, Acta medica Scandinavica.

[141]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[142]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[143]  N. Bundred,et al.  Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence , 2006, British Journal of Cancer.

[144]  N. Ishiguro,et al.  Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. , 2006, Carcinogenesis.

[145]  M. Kralj,et al.  Fenoprofen and Ketoprofen Amides as Potential Antitumor Agents , 2007, Chemical biology & drug design.

[146]  K. Lundholm,et al.  EP1–4 subtype, COX and PPARγ receptor expression in colorectal cancer in prediction of disease‐specific mortality , 2007, International journal of cancer.

[147]  I. Morita Distinct functions of COX-1 and COX-2. , 2002, Prostaglandins & other lipid mediators.

[148]  R. McLeod,et al.  Nonsteroidal Anti-inflammatory Drugs and Aspirin for the Prevention of Colorectal Adenomas and Cancer: A Systematic Review , 2004, Diseases of the colon and rectum.

[149]  E. Fernandes,et al.  The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species. , 2003, Free radical biology & medicine.

[150]  D. Frisbie,et al.  Nonsteroidal antiinflammatory drugs. , 1981, Delaware medical journal.

[151]  Dairong Wang,et al.  Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.

[152]  J. Rokach,et al.  Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. , 2005, Progress in lipid research.

[153]  B. Thiele,et al.  The diversity of the lipoxygenase family , 1999, FEBS letters.

[154]  J. Pelletier,et al.  The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein , 2006, Arthritis research & therapy.

[155]  T. Eling,et al.  Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate , 2002, The Journal of Biological Chemistry.

[156]  F. Traganos,et al.  Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. , 2001, Cancer research.

[157]  P. van’t Veer,et al.  Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC study. European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. , 1998, American journal of epidemiology.

[158]  Lawrence J Marnett,et al.  A Novel Mechanism of Cyclooxygenase-2 Inhibition Involving Interactions with Ser-530 and Tyr-385* , 2003, Journal of Biological Chemistry.

[159]  J. Fraumeni,et al.  Cancer mortality among Alaskan natives, 1960-69. , 1975, Journal of the National Cancer Institute.

[160]  J. Falck,et al.  Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. , 2000, Journal of lipid research.

[161]  P. Loll,et al.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1 , 1994, Nature.

[162]  J. J. Moreno,et al.  Role of EP(1) and EP(4) PGE(2) subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. , 2002, American journal of physiology. Cell physiology.

[163]  N. Abraham,et al.  Overexpression of the Heme Oxygenase Gene in Renal Cell Carcinoma , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[164]  M. Murakami,et al.  Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A(2)s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. , 1999, The Journal of biological chemistry.

[165]  A. Brash,et al.  15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. , 1999, The American journal of pathology.

[166]  D. Elder,et al.  The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  S. Matsumoto,et al.  Novel Antiarthritic Agents with 1,2‐Isothiazolidine‐1,1‐dioxide (γ‐Sultam) Skeleton: Cytokine Suppressive Dual Inhibitors of Cyclooxygenase‐2 and 5‐Lipoxygenase. , 2000 .

[168]  J. Falgueyret,et al.  Sensitivity of immunoaffinity-purified porcine 5-lipoxygenase to inhibitors and activating lipid hydroperoxides. , 1989, Biochemical pharmacology.

[169]  M. Laviolette,et al.  Inhibitory effects of MK‐886 on arachidonic acid metabolism in human phagocytes , 1990, British journal of pharmacology.

[170]  L. Marnett,et al.  Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. , 1998, Journal of medicinal chemistry.

[171]  I. Weinstein,et al.  Select Cyclic Nucleotide Phosphodiesterase Inhibitors in Colon Tumor Chemoprevention and Chemotherapy , 2004 .

[172]  C. Serhan,et al.  Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[173]  C. Sen,et al.  Antioxidant and redox regulation of gene transcription , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[174]  K. Druey,et al.  Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.

[175]  N. Farman,et al.  Segmental synthesis and actions of prostaglandins along the nephron. , 1987, The American journal of physiology.

[176]  J. Falgueyret,et al.  LTA4-derived 5-oxo-eicosatetraenoic acid: pH-dependent formation and interaction with the LTB4 receptor of human polymorphonuclear leukocytes , 2000 .

[177]  V. Ziboh,et al.  Biological significance of essential fatty acids/prostanoids/ lipoxygenase-derived monohydroxy fatty acids in the skin , 2002, Archives of pharmacal research.

[178]  D. Beer,et al.  Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis , 2004, Clinical Cancer Research.

[179]  R. Hunt,et al.  The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events , 2003, American Journal of Gastroenterology.

[180]  G. Watkins,et al.  Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. , 2006, Prostaglandins, leukotrienes, and essential fatty acids.

[181]  J. Schwab,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[182]  S. Ishii,et al.  Mutagenesis studies on the amino acid residues involved in the iron-binding and the activity of human 5-lipoxygenase. , 1992, Biochemical and biophysical research communications.

[183]  M. Leshno,et al.  MF tricyclic and sulindac retard tumor formation in an animal model , 2006, International journal of cancer.

[184]  L. Horrocks,et al.  Signaling and interplay mediated by phospholipases A2, C, and D in LA-N-1 cell nuclei. , 2005, Reproduction, nutrition, development.

[185]  J. J. Moreno,et al.  Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth Published, JLR Papers in Press, September 16, 2006. , 2006, Journal of Lipid Research.

[186]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[187]  Hiromasa Hashimoto,et al.  4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1). , 2002, Journal of medicinal chemistry.

[188]  D. Riendeau,et al.  Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. , 2005, The Biochemical journal.

[189]  S. Laufer,et al.  The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2 , 2002, Inflammation Research.

[190]  Charles N. Serhan,et al.  Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.

[191]  Jian-Kang Chen,et al.  Cytochrome P450 Epoxygenase Metabolism of Arachidonic Acid Inhibits Apoptosis , 2001, Molecular and Cellular Biology.

[192]  Tavares The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa , 2000, Alimentary pharmacology & therapeutics.

[193]  Megumi Baba,et al.  Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2. , 2003, Cancer letters.

[194]  Soo Young Lee,et al.  Molecular ordering of ROS production, mitochondrial changes, and caspase activation during sodium salicylate-induced apoptosis. , 2003, Free radical biology & medicine.

[195]  W C Willett,et al.  Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.

[196]  K. Sugihara,et al.  JTE‐522, a selective COX‐2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: A vascular cast model study , 2004, International journal of cancer.

[197]  A. Ljubimov,et al.  P450 in the angiogenesis affair: the unusual suspect. , 2005, The American journal of pathology.

[198]  A. Plückthun,et al.  Rate-determining step in phospholipase A2 mechanism. 18O isotope exchange determined by 13C NMR. , 1986, The Journal of biological chemistry.

[199]  Rajnish A. Gupta,et al.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.

[200]  Oliver Werz,et al.  Therapeutic options for 5-lipoxygenase inhibitors. , 2006, Pharmacology & therapeutics.

[201]  M. Kondo,et al.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer. , 1995, Cancer research.

[202]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[203]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[204]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[205]  K. Matsuo,et al.  Breast cancer risk and erythrocyte compositions of n‐3 highly unsaturated fatty acids in Japanese , 2007, International journal of cancer.

[206]  J. Mulshine,et al.  Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. , 1999, Cancer research.

[207]  R. Copeland,et al.  Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[208]  Y. Denkins,et al.  Role of omega-3 polyunsaturated fatty acids on cyclooxygenase-2 metabolism in brain-metastatic melanoma. , 2005, Journal of lipid research.

[209]  Magnus Ingelman-Sundberg,et al.  Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. , 2004, The American journal of clinical nutrition.

[210]  P. Duke,et al.  Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.

[211]  V. Strand,et al.  Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis , 2004, American journal of therapeutics.

[212]  T. Adrian,et al.  Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[213]  Ding Ma,et al.  Cytochrome p450 epoxygenase promotes human cancer metastasis. , 2007, Cancer research.

[214]  J. Chow,et al.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.

[215]  C. Bombardier,et al.  Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison , 2006, The Lancet.

[216]  E. Jacobs,et al.  VEGF-induced relaxation of pulmonary arteries is mediated by endothelial cytochrome P-450 hydroxylase. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[217]  G. Cabral Lipids as bioeffectors in the immune system. , 2005, Life sciences.